Cassava Sciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 29
- Market Cap
- -
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06390410
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
- Conditions
- AbsorptionMetabolismExcretion
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06195319
- Locations
- 🇺🇸
Fortrea, Madison, Wisconsin, United States
Open-label Extension for Phase 3 Clinical Trials of Simufilam
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 1081
- Registration Number
- NCT05575076
- Locations
- 🇺🇸
MDFirst Research, Chandler, Arizona, United States
🇺🇸CCT Research - Gilbert Neurology Partners, Gilbert, Arizona, United States
🇺🇸Xenoscience, Inc., Phoenix, Arizona, United States
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05352763
- Locations
- 🇺🇸
Cognitive Clinical Trials, Papillion, Nebraska, United States
🇺🇸Valley Research Center, Inc., Imperial, California, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 1125
- Registration Number
- NCT05026177
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
🇺🇸Clinical Endpoints, Scottsdale, Arizona, United States
- Prev
- 1
- 2
- Next
News
Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development
• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases. • Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact. • MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned. • The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.